DDAVP ( DrugBank: dDAVP )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
75	クッシング病	2
288	自己免疫性後天性凝固因子欠乏症	4

75. クッシング病

臨床試験数 : 205 / 薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs021180039	24/05/2018	26/03/2019	The usefulness of DDAVP test and GHRP-2 test in patients with Cushing's disease	The usefulness of DDAVP test and GHRP-2 test in patients with Cushing's disease - Cushing_diagnosis	Cushing's disease	administration of DDAVP or GHRP-2	Kageyama Kazunori	NULL	Recruiting	>= 15age old	Not applicable	Both	15	Phase 3	Japan
2	JPRN-UMIN000018891	2015/10/01	01/10/2015	The usefulness of DDAVP test and GHRP-2 test in patients with Cushing's disease	The usefulness of DDAVPtest and GHRP-2 test in patients with Cushing's disease - The usefulness of D ...	Cushing's disease	administration of DDAVP or GHRP-2	Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine	NULL	Recruiting	15years-old	Not applicable	Male and Female	15	Not selected	Japan

First Previous1Next Last

288. 自己免疫性後天性凝固因子欠乏症

臨床試験数 : 206 / 薬物数 : 231 - (DrugBank : 28) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 21

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-001631-46-NL (EUCTR)	14/02/2019	13/02/2019	Effects of pharmacokinetic models in dosing of DDAVPand/or von Willebrand factor-containing concentr ...	Implementation of pharmacokinetic-guided dosing of DDAVPand VWF-containing concentrates in von Wille ...	Von Willebrand disease MedDRA version: 20.0;Level: LLT;Classification code 10055168;Term: Von Willeb ...	Trade Name: Minrin INN or Proposed INN: DESMOPRESSIN Trade Name: Octostim INN or Proposed INN: DESMOPRE ...	Erasmus University Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Phase 4	Netherlands
2	NCT00994929 (ClinicalTrials.gov)	January 2010	12/10/2009	Efficacy and Safety of IL-11 in DDAVP Unresponsive	Phase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Mo ...	Hemophilia A;Von Willebrand Disease	Biological: Neumega (Oprelvekin, Interleukin 11, IL-11)	University of Pittsburgh	NULL	Completed	18 Years	N/A	All	9	Phase 2	United States
3	EUCTR2006-001383-23-IT (EUCTR)	30/06/2006	28/11/2006	Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly pur ...	Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly pur ...	patients with severe inherited VWD unresponsive to DDAVPand with frequent bleedings MedDRA version: ...	Trade Name: ALPHANATE*INF 1F 1500UI+F 10ML INN or Proposed INN: Coagulation factor VIII Trade Name: FA ...	FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 3	Spain;Germany;United Kingdom;Italy
4	EUCTR2005-004496-38-DK (EUCTR)	22/06/2006	09/05/2006	Desmopressin in the management of von Willebrand disease; Biological versus clinical efficacy.	Desmopressin in the management of von Willebrand disease; Biological versus clinical efficacy.	von Willebrand disease (VWD) is an inherited bleeding disorder, characterised mainly by mucosal blee ...	Trade Name: Octostim Product Name: Octostim Product Code: DDAVP(Desmopressin) Trade Name: Octostim Produ ...	Rigshospitalet, Copenhagen	NULL	Not Recruiting			Female: yes Male: yes	150	Phase 4	Denmark

First Previous1Next Last

先頭へ